Report Content
Chapter 1 Methodology
1.1 Methodology
1.2 Market scope and definition
1.3 Base estimates and calculations
1.4 Forecast calculations
1.5 Data sources
1.5.1 Primary
1.5.2 Secondary
1.5.2.1 Paid sources
1.5.2.2 Unpaid sources
Chapter 2 Executive Summary
2.1 Cancer biomarkers market, 2018 - 2032
2.1.1 Business trends
2.1.2 Biomarker type trends
2.1.3 Cancer type trends
2.1.4 Technology trends
2.1.5 Application trends
2.1.6 Regional trends
Chapter 3 Cancer Biomarkers Market Industry Insights
3.1 Industry ecosystem analysis
3.2 Vendor matrix
3.3 Industry impact forces
3.3.1 Growth drivers
3.3.1.1 Increasing prevalence of various types of cancers
3.3.1.2 Technological advancements
3.3.1.3 Increasing investments by government organizations
3.3.2 Industry pitfalls & challenges
3.3.2.1 High treatment cost
3.3.2.2 Unfavorable reimbursement policies
3.4 Growth potential analysis
3.4.1 By biomarker type
3.4.2 By cancer type
3.4.3 By technology
3.4.4 By application
3.4.5 By region
3.5 Regulatory scenario
3.5.1 U.S.
3.5.2 Canada
3.5.3 Europe
3.6 Porter's analysis
3.6.1 Industry rivalry
3.6.2 Buyer power
3.6.3 Supplier power
3.6.4 Threat of substitute
3.6.5 Threat of new entrants
3.7 PESTEL analysis
3.7.1 Political
3.7.2 Economical
3.7.3 Social
3.7.4 Technological
3.7.5 Environmental
3.7.6 Legal
Chapter 4 Competitive Landscape, 2022
4.1 Introduction
4.2 Product portfolio matrix
4.2.1 Abbott Laboratories
4.2.2 Bio-Rad Laboratories, Inc.
4.2.3 Bristol-Myers Squibb Company
4.2.4 Exact Sciences Corporation
4.2.5 F. Hoffmann-La Roche Ltd.
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategic outlook matrix
Chapter 5 Cancer Biomarkers Market, By Biomarker Type
5.1 Key segment trends
5.2 Protein Biomarkers
5.2.1 Market size, by region, 2018 - 2032 (USD Million)
5.3 Genetic Biomarkers
5.3.1 Market size, by region, 2018 - 2032 (USD Million)
Chapter 6 Cancer Biomarkers Market, By Cancer Type
6.1 Key segment trends
6.2 Breast Cancer
6.2.1 Market size, by region, 2018 - 2032 (USD Million)
6.3 Lung Cancer
6.3.1 Market size, by region, 2018 - 2032 (USD Million)
6.4 Colorectal Cancer
6.4.1 Market size, by region, 2018 - 2032 (USD Million)
6.5 Prostate Cancer
6.5.1 Market size, by region, 2018 - 2032 (USD Million)
6.6 Melanoma
6.6.1 Market size, by region, 2018 - 2032 (USD Million)
6.7 Leukemia
6.7.1 Market size, by region, 2018 - 2032 (USD Million)
6.8 Thyroid Cancer
6.8.1 Market size, by region, 2018 - 2032 (USD Million)
6.9 Non-Hodgkin's Lymphoma
6.9.1 Market size, by region, 2018 - 2032 (USD Million)
6.10 Kidney Cancer
6.10.1 Market size, by region, 2018 - 2032 (USD Million)
6.11 Bladder Cancer
6.11.1 Market size, by region, 2018 - 2032 (USD Million)
6.12 Other Cancers
6.12.1 Market size, by region, 2018 - 2032 (USD Million)
Chapter 7 Cancer Biomarkers Market, By Technology
7.1 Key segment trends
7.2 Omics Technology
7.2.1 Market size, by region, 2018 - 2032 (USD Million)
7.2.1.1 Proteomics
7.2.1.1.1 Market size, by region, 2018 - 2032 (USD Million)
7.2.1.2 Genomics
7.2.1.2.1 Market size, by region, 2018 - 2032 (USD Million)
7.2.1.3 PCR
7.2.1.3.1 Market size, by region, 2018 - 2032 (USD Million)
7.2.1.4 Others
7.2.1.4.1 Market size, by region, 2018 – 2032 (USD Million)
7.3 Imaging Technology
7.3.1 Market size, by region, 2018 – 2032 (USD Million)
7.3.1.1 Ultrasound
7.3.1.1.1 Market size, by region, 2018 – 2032 (USD Million)
7.3.1.2 CT
7.3.1.2.1 Market size, by region, 2018 – 2032 (USD Million)
7.3.1.3 MRI
7.3.1.3.1 Market size, by region, 2018 – 2032 (USD Million)
7.3.1.4 PET
7.3.1.4.1 Market size, by region, 2018 – 2032 (USD Million)
7.3.1.5 Mammography
7.3.1.5.1 Market size, by region, 2018 – 2032 (USD Million)
7.4 Immunoassays
7.4.1 Market size, by region, 2018 – 2032 (USD Million)
7.5 Bioinformatics
7.5.1 Market size, by region, 2018 – 2032 (USD Million)
7.6 Cytogenetics
7.6.1 Market size, by region, 2018 – 2032 (USD Million)
7.6.1.1 In situ
7.6.1.1.1 Market size, by region, 2018 – 2032 (USD Million)
7.6.1.2 Others
7.6.1.2.1 Market size, by region, 2018 – 2032 (USD Million)
Chapter 8 Cancer Biomarkers Market, By Application
8.1 Key segment trends
8.2 Diagnostics
8.2.1 Market size, by region, 2018 – 2032 (USD Million)
8.3 Research and Development
8.3.1 Market size, by region, 2018 – 2032 (USD Million)
8.4 Prognostics
8.4.1 Market size, by region, 2018 – 2032 (USD Million)
8.5 Risk Assessment
8.5.1 Market size, by region, 2018 – 2032 (USD Million)
8.6 Others
8.6.1 Market size, by region, 2018 – 2032 (USD Million)
Chapter 9 Cancer Biomarkers Market, By Region
9.1 Key regional trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Switzerland
9.3.7 Rest of Europe
9.4 Asia Pacific
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Australia
9.4.5 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Rest of Latin America
9.6 MEA
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 Rest of Middle East & Africa
Chapter 10 Company Profiles
10.1 Abbott Laboratories
10.1.1 Business overview
10.1.2 Financial data
10.1.3 Product landscape
10.1.4 Strategic outlook
10.1.5 SWOT analysis
10.2 Bio-Rad Laboratories, Inc.
10.2.1 Business overview
10.2.2 Financial data
10.2.3 Product landscape
10.2.4 Strategic outlook
10.2.5 SWOT analysis
10.3 Bristol-Myers Squibb Company
10.3.1 Business overview
10.3.2 Financial data
10.3.3 Product landscape
10.3.4 Strategic outlook
10.3.5 SWOT analysis
10.4 Exact Sciences Corporation
10.4.1 Business overview
10.4.2 Financial data
10.4.3 Product landscape
10.4.4 Strategic outlook
10.4.5 SWOT analysis
10.5 F. Hoffmann-La Roche Ltd.
10.5.1 Business overview
10.5.2 Financial data
10.5.3 Product landscape
10.5.4 Strategic outlook
10.5.5 SWOT analysis
10.6 Merck KGaA
10.6.1 Business overview
10.6.2 Financial data
10.6.3 Product landscape
10.6.4 Strategic outlook
10.6.5 SWOT analysis
10.7 PerkinElmer, Inc.
10.7.1 Business overview
10.7.2 Financial data
10.7.3 Product landscape
10.7.4 Strategic outlook
10.7.5 SWOT analysis
10.8 Qiagen N.V.
10.8.1 Business overview
10.8.2 Financial data
10.8.3 Product landscape
10.8.4 Strategic outlook
10.8.5 SWOT analysis
10.9 Siemens AG
10.9.1 Business overview
10.9.2 Financial data
10.9.3 Product landscape
10.9.4 Strategic outlook
10.9.5 SWOT analysis
10.10 Thermo Fisher Scientific, Inc.
10.10.1 Business overview
10.10.2 Financial data
10.10.3 Product landscape
10.10.4 Strategic outlook
10.10.5 SWOT analysis
10.11 Enzo Biochem, Inc.
10.11.1 Business overview
10.11.2 Financial data
10.11.3 Product landscape
10.11.4 Strategic outlook
10.11.5 SWOT analysis
10.12 Charles River Laboratories
10.12.1 Business overview
10.12.2 Financial data
10.12.3 Product landscape
10.12.4 Strategic outlook
10.12.5 SWOT analysis
10.13 Eurofins Scientific
10.13.1 Business overview
10.13.2 Financial data
10.13.3 Product landscape
10.13.4 Strategic outlook
10.13.5 SWOT analysis
10.14 Agilent Technologies, Inc.
10.14.1 Business overview
10.14.2 Financial data
10.14.3 Product landscape
10.14.4 Strategic outlook
10.14.5 SWOT analysis
10.15 Bruker
10.15.1 Business overview
10.15.2 Financial data
10.15.3 Product landscape
10.15.4 Strategic outlook
10.15.5 SWOT analysis
